PubMed
Intranasal oxytocin in humans: a review of neurobiological and behavioral effects
Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 25–50 mcg · Most common: 25–50 mcg
Reports span 0–400 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 89% said they felt similar to their last entry, 11% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 175 days · Based on 27 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 38% · Mixed 62% · Unfavorable overall 0%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 63 days · Based on 40 repeat reporters
Published sources linked on the Oxytocin and TB-500 wiki pages.
PubMed
Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013
FDA Drug Label
Par Pharmaceutical. FDA Drug Label. 2014
PubMed
Heinrichs M, Baumgartner T, Kirschbaum C, et al. Biological psychiatry. 2003
PubMed
Yin H, Jiang M, Han T, et al. Peptides. 2024
PubMed
Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010
PubMed
Smart N, Riley PR. Ann N Y Acad Sci. 2012
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Goldstein AL, Hannappel E, Sosne G, et al. Expert opinion on biological therapy. 2012
PubMed
Li X, Zheng L, Peng F, et al. Protein expression and purification. 2007
PubMed
Mayfield CK, Bolia IK, Feingold CL, et al. Am J Sports Med. 2026
PubMed
Rahman OF, Lee SJ, Seeds WA. JAAOS Glob Res Rev. 2026